Theriva Biologics Inc. Common Stock (TOVX)
Stock · AMEX · Health Care
$0.21as of 10/16/2026
Price chart
Active signals
TOVX Signal Track Record
How signals performed across all stocks →What TOVX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 26 | -10.5% | 23% | September 28, 2026 |
| Bollinger Band Breakdown | 26 | -1.3% | 46% | September 25, 2026 |
| Bollinger Band Breakout | 17 | -26.0% | 18% | April 20, 2026 |
| 200-Day Moving Average TouchActive now | 4 | -10.7% | 0% | September 10, 2026 |
| Any 20-session window (baseline) | -7.7% | 30% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TOVX
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 15
- Website
- therivabio.com/
Fundamentals
- 1-day range
- $0.2077$0.2161
- Market cap
- $10.32M
- P/E (trailing)
- —
- P/E (forward)
- -1.04
- EPS (trailing)
- $-0.64
- Dividend yield
- —
- Beta
- 1.25
- Avg. volume
- 523.5K
- Dividend pay date
- August 13, 2018
Forecasts
2 analyst ratings
Theriva Biologics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- TOVXTheriva Biologics Inc. Common Stock$0.21▲ 0.00%Market cap $10.32MP/E —$0.1628$0.8632
- ADILAdial Pharmaceuticals Inc Common Stock$3.49▲ 11.15%Market cap $10.29MP/E —$1.31$232.5
- BIVIBioVie Inc. Class A Common Stock$1.2▲ 6.19%Market cap $10.18MP/E —$0.82$3.79
- LSTALisata Therapeutics Inc. Common Stock$1.03▼ 3.74%Market cap $9.74MP/E —$0.98$5.07
- BFRGBullfrog AI Holdings Inc. Common Stock$0.513▼ 4.11%Market cap $10.96MP/E —$0.4251$1.96
- LNAILunai Bioworks Inc. Common Stock$0.68▼ 17.68%Market cap $10.97MP/E —$0.8757$13.28
- GDTCCytoMed Therapeutics Limited Ordinary Shares$0.88▲ 1.15%Market cap $9.50MP/E —$0.6801$3.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TOVX Theriva Biologics Inc. Common Stock | $10.32M | — | $0.21 | ▲ 0.00% | $0.1628$0.8632 |
| ADIL Adial Pharmaceuticals Inc Common Stock | $10.29M | — | $3.49 | ▲ 11.15% | $1.31$232.5 |
| BIVI BioVie Inc. Class A Common Stock | $10.18M | — | $1.2 | ▲ 6.19% | $0.82$3.79 |
| LSTA Lisata Therapeutics Inc. Common Stock | $9.74M | — | $1.03 | ▼ 3.74% | $0.98$5.07 |
| BFRG Bullfrog AI Holdings Inc. Common Stock | $10.96M | — | $0.513 | ▼ 4.11% | $0.4251$1.96 |
| LNAI Lunai Bioworks Inc. Common Stock | $10.97M | — | $0.68 | ▼ 17.68% | $0.8757$13.28 |
| GDTC CytoMed Therapeutics Limited Ordinary Shares | $9.50M | — | $0.88 | ▲ 1.15% | $0.6801$3.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Theriva Biologics Announces Nature Medicine Publication Of Phase 2b VCN-01 Data In Metastatic Pancreatic Cancerbenzinga · 9/30/2026
- Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature MedicineYahoo · 9/30/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 1.72M
- Total value held
- $288.0K
- Institutional holders
- 21
- Unknown450.3K
- Unknown253.2K
- Unknown225.6K
- Unknown192.4K
- Unknown177.0K
- Unknown112.1K
- Unknown105.2K
- Unknown94.6K
- Unknown27.6K
- Unknown23.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
TOVX: VCN-01 Phase 2b Results Published in Nature Medicine
Theriva Biologics announced that the results of its Phase 2b VIRAGE trial for VCN‑01 in metastatic pancreatic cancer were published in Nature Medicine. The study’s findings could affect how the market views the drug’s potential. The stock is trading near its 200‑day moving average and has an RSI of 50.5, indicating a neutral trend.
TOVX: VCN-01 Phase 2b Results Published in Nature Medicine. Theriva Biologics announced that the results of its Phase 2b VIRAGE trial for VCN‑01 in metastatic pancreatic cancer were published in Nature Medicine. The study’s findings could affect how the market views the drug’s potential. The stock is trading near its 200‑day moving average and has an RSI of 50.5, indicating a neutral trend.